公开(公告)号：US20240325369A1

公开(公告)日：2024-10-03

申请号：US18580583

申请日：2022-07-18

申请人： Janssen Pharmaceutica NV

发明人： Peter Francis ,  Angela Mennicke LOPEZ-GITLITZ ,  Natalie A NUTNICK ,  Gary Edward MASON ,  Xin ZHAO ,  Michael P GORMLEY ,  Yuangen ZHU ,  Karen Ann URTISHAK ,  Shibu THOMAS ,  Adam A Del Corral

IPC分类号： A61K31/454 ,  A61K9/00 ,  A61P35/00

CPC分类号： A61K31/454 ,  A61K9/0053 ,  A61P35/00

摘要： The present invention relates to a method of improving the efficacy of treatment of line 2+ metastatic castration-resistant prostate cancer (mCRPC) with biallelic DNA-repair anomalies in a male human, wherein said biallelic DNA-repair anomalies are selected from: i) BRCA (BRCA1, BRCA2, or a combination thereof), ii) non-BRCA (ATM, FANCA, PALB2, CHEK2, BRIP1, HDAC2, or any combination thereof): or iii) any combination thereof; wherein the male human has received prior taxane-based chemotherapy and androgen receptor (AR)-targeted therapy; said method of improving the efficacy of treatment comprising administering to said male human a once-daily oral dosing of 300 mg niraparib.